

In the Claims:

Please amend claims 1-13 and 15-35 as follows:

1. (Amended) A method for ameliorating the harmful effects of TNF in an animal, comprising administering to an animal in need of such treatment a therapeutically effective amount of a recombinant polypeptide having the ability to bind TNF, wherein said polypeptide is encoded by a nucleic acid molecule comprising the nucleotide sequence as set forth in any of SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, residues 4 through 549 of SEQ ID NO: 9, residues 4 through 519 of SEQ ID NO: 15, or residues 4 through 516 of SEQ ID NO: 19.

2. (Amended) The method of Claim 1, wherein the nucleic acid molecule comprises the nucleotide sequence as set forth in SEQ ID NO: 9.

3. (Amended) The method of Claim 1, wherein the nucleic acid molecule comprises the nucleotide sequence as set forth in SEQ ID NO: 15.

4. (Amended) The method of Claim 1, wherein the nucleic acid molecule comprises the nucleotide sequence as set forth in SEQ ID NO: 19.

5. (Amended) The method of Claim 1, wherein the nucleic acid molecule comprises the nucleotide sequence as set forth in SEQ ID NO: 5.

6. (Amended) The method of Claim 1, wherein the nucleic acid molecule comprises the nucleotide sequence as set forth in SEQ ID NO: 7.

7. (Amended) The method of Claim 1, wherein the nucleic acid molecule comprises the nucleotide sequence as set forth in SEQ ID NO: 13.

8. (Amended) The method of Claim 1, wherein the nucleic acid molecule comprises the

nucleotide sequence as set forth in SEQ ID NO: 11.

9. (Amended) The method of Claim 1, wherein the nucleic acid molecule comprises the nucleotide sequence as set forth in SEQ ID NO: 17.

10. (Amended) The method of Claim 1, wherein the nucleic acid molecule comprises residues 4 through 549 of the nucleotide sequence as set forth in SEQ ID NO: 9.

11. (Amended) The method of Claim 1, wherein the nucleic acid molecule comprises residues 4 through 519 of the nucleotide sequence as set forth in SEQ ID NO: 15.

B1
Cont
12. (Amended) The method of Claim 1, wherein the nucleic acid molecule comprises residues 4 through 516 of the nucleotide sequence as set forth in SEQ ID NO: 19.

13. (Amended) The method of Claim 1, wherein the nucleic acid molecule comprises the nucleotide sequence as set forth in SEQ ID NO: 3.

B2
15. (Amended) A method for ameliorating the harmful effects of TNF in an animal, comprising administering to an animal in need of such treatment a therapeutically effective amount of a recombinant polypeptide having the ability to bind TNF, wherein said polypeptide comprises the amino acid sequence as set forth in any of SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, residues 2 through 183 of SEQ ID NO: 10, residues 2 through 173 of SEQ ID NO: 16, or residues 2 through 172 of SEQ ID NO: 20; and

wherein said polypeptide has:

- a) at least one conservative amino acid substitution;
- b) at least one amino acid substitution at a glycosylation site;
- c) at least one amino acid substitution at a proteolytic cleavage site;
- d) at least one amino acid substitution at a cysteine residue;
- e) at least one amino acid deletion;
- f) at least one amino acid insertion;

- g) a C- and/or N-terminal truncation; or
- h) a combination of modifications selected from the group consisting of conservative amino acid substitutions, amino acid substitutions at a glycosylation site, amino acid substitutions at a proteolytic cleavage site, amino acid substitutions at a cysteine residue, amino acid deletions, amino acid insertions, C-terminal truncation, and N-terminal truncation.

16. (Amended) The method of Claim 15, wherein said encoded polypeptide has at least one conservative amino acid substitution.

17. (Amended) The method of Claim 15, wherein said encoded polypeptide has at least one amino acid substitution at a glycosylation site.

18. (Amended) The method of Claim 15, wherein said encoded polypeptide has at least one amino acid substitution at a proteolytic cleavage site.

19. (Amended) The method of Claim 15, wherein said encoded polypeptide has at least one amino acid substitution at a cysteine residue.

20. (Amended) The method of Claim 15, wherein said encoded polypeptide has at least one amino acid deletion.

21. (Amended) The method of Claim 15, wherein said encoded polypeptide has at least one amino acid insertion.

22. (Amended) The method of Claim 15, wherein said encoded polypeptide has a C- and/or N-terminal truncation.

23. (Amended) A method for ameliorating the harmful effects of TNF in an animal, comprising administering to an animal in need of such treatment a therapeutically effective amount of a recombinant polypeptide having the ability to bind TNF, wherein said polypeptide comprises the amino acid sequence as set forth in any of SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ

ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, residues 2 through 183 of SEQ ID NO: 10, residues 2 through 173 of SEQ ID NO: 16, or residues 2 through 172 of SEQ ID NO: 20.

24. (Amended) The method of Claim 23, wherein said encoded polypeptide comprises the amino acid sequence as set forth in SEQ ID NO: 10.

25. (Amended) The method of Claim 23, wherein said encoded polypeptide comprises the amino acid sequence as set forth in SEQ ID NO: 16.

26. (Amended) The method of Claim 23, wherein said encoded polypeptide comprises the amino acid sequence as set forth in SEQ ID NO: 20.

27. (Amended) The method of Claim 23, wherein said encoded polypeptide comprises the amino acid sequence as set forth in SEQ ID NO: 6.

B2
cont
28. (Amended) The method of Claim 23, wherein said encoded polypeptide comprises the amino acid sequence as set forth in SEQ ID NO: 8.

29. (Amended) The method of Claim 23, wherein said encoded polypeptide comprises the amino acid sequence as set forth in SEQ ID NO: 14.

30. (Amended) The method of Claim 23, wherein said encoded polypeptide comprises the amino acid sequence as set forth in SEQ ID NO: 12.

31. (Amended) The method of Claim 23, wherein said encoded polypeptide comprises the amino acid sequence as set forth in SEQ ID NO: 18.

32. (Amended) The method of Claim 23, wherein said encoded polypeptide comprises residues 2 through 183 of the amino acid sequence as set forth in SEQ ID NO: 10.

duplicate

30. (Amended) The method of Claim 23, wherein said encoded polypeptide comprises the amino acid sequence as set forth in SEQ ID NO: 12.

duplicate

31. (Amended) The method of Claim 23, wherein said encoded polypeptide comprises the amino acid sequence as set forth in SEQ ID NO: 18.

32. (Amended) The method of Claim 23, wherein said encoded polypeptide comprises residues 2 through 183 of the amino acid sequence as set forth in SEQ ID NO: 10.

33. (Amended) The method of Claim 23, wherein said encoded polypeptide comprises residues 2 through 173 of the amino acid sequence as set forth in SEQ ID NO: 16.

B3

34. (Amended) The method of Claim 23, wherein said encoded polypeptide comprises residues 2 through 172 of the amino acid sequence as set forth in SEQ ID NO: 20.


35. (Amended) The method of Claim 23, wherein said encoded polypeptide comprises the amino acid sequence as set forth in SEQ ID NO: 4.

REMARKS

Applicants contend that no new matter has been added as a result of the above-described amendments. Applicants respectfully request that the Examiner direct any inquiries regarding this communication to the undersigned representative at (312) 913-0001.

Respectfully submitted,
McDonnell Boenhen Hulbert & Berghoff

Dated: January 29, 2002

By: 
Donald L. Zuhn, Ph.D.
Reg. No. 48,710